En­thused by PhII au­toim­mune da­ta, J&J kept Mo­men­ta wait­ing in the lead-up to $6.5B buy­out

Mo­men­ta had been talk­ing to J&J for well over a year about a po­ten­tial part­ner­ship when it was due to re­lease Phase II da­ta for its lead drug, nipocal­imab (M281), in myas­the­nia gravis. Hav­ing es­tab­lished a line of con­tact dur­ing the 2019 JP Mor­gan con­fer­ence, Mo­men­ta CEO Craig Wheel­er raised the pos­si­bil­i­ty of a buy­out in Oc­to­ber. For months, J&J kept ask­ing more ques­tions about both nipocal­imab and a sec­ond com­pound, M254.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER